STUDY DESIGN OF A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN ANTAGONIST, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)-MedSci.cn

STUDY DESIGN OF A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN ANTAGONIST, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)

Murakhovskaya, I; Fattizzo, B; Cueto, D; Jouvin, MH

ANNALS OF THE RHEUMATIC DISEASES, 2022; 81 (): 1751

科室
- - 订阅+
  - 更多科室
工具
服务